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Abstract
SRY-related high-mobility-group box 9 (Sox9) gene is a cartilage-specific transcription factor that plays essential roles in
chondrocyte differentiation and cartilage formation. The aim of this study was to investigate the feasibility of genetic delivery of
Sox9 to enhance chondrogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells (hUC-MSCs).
After they were isolated from human umbilical cord blood within 24 h after delivery of neonates, hUC-MSCs were untreated or
transfected with a human Sox9-expressing plasmid or an empty vector. The cells were assessed for morphology and
chondrogenic differentiation. The isolated cells with a fibroblast-like morphology in monolayer culture were positive for the MSC
markers CD44, CD105, CD73, and CD90, but negative for the differentiation markers CD34, CD45, CD19, CD14, or major
histocompatibility complex class II. Sox9 overexpression induced accumulation of sulfated proteoglycans, without altering the
cellular morphology. Immunocytochemistry demonstrated that genetic delivery of Sox9 markedly enhanced the expression of
aggrecan and type II collagen in hUC-MSCs compared with empty vector-transfected counterparts. Reverse transcription-
polymerase chain reaction analysis further confirmed the elevation of aggrecan and type II collagen at the mRNA level in Sox9-
transfected cells. Taken together, short-term Sox9 overexpression facilitates chondrogenesis of hUC-MSCs and may thus
have potential implications in cartilage tissue engineering.
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Introduction
Cartilage regeneration is often needed in orthopedic or
plastic surgery for the repair of cartilaginous defects.
However, due to the limited regenerative capacity of
cartilage tissue, the treatment of various cartilaginous
lesions remains a challenge to clinicians. The focal
treatment strategies for osteochondral defects are cur-
rently associated with a variety of risks and limitations
including inadequate availability of donor tissues, donor
site morbidity, and poor attachment of the graft to the
surrounding chondral surface (1). Tissue engineering has
emerged as a promising new method for cartilage repair in
which a combination of cells, scaffolding, and bioactive
agents are used to fabricate functionally engineered
cartilage tissue (2).
The cell source is an important factor for successful
tissue engineering, and chondrocytes that can be
expanded in vitro have been commonly used in cartilage
tissue engineering (3). However, the relatively low
availability and proliferation potential of chondrocytes
hamper their application in tissue engineering. In vitro
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expansion is accompanied by chondrocyte dedifferentia-
tion, resulting in substantial molecular and phenotypic
changes (4). Dedifferentiated chondrocytes show
decreased proteoglycan synthesis and type II collagen
expression and increased type I collagen expression, thus
failing to produce a mechanically normal cartilage extra-
cellular matrix (ECM).
In addition to chondrocytes, stem cells have also been
explored for the repair of damaged cartilage (5).
Mesenchymal stem cells (MSCs) are a population of
multipotent cells that can differentiate into different cellular
lineages including not only osteoblasts, chondrocytes,
and adipocytes but also muscle cells, cardiomyocytes,
and neural precursors (6-8). MSCs have been identified in
a broad range of tissues including bone marrow, adipose
tissue, synovial tissue, and umbilical cord blood (9).
Umbilical cord blood is an important source of human
MCSs, and the isolation of MSCs from umbilical cord has
potential advantages over isolation from bone marrow,
including simplicity, cost effectiveness, and noninvasive-
ness. Moreover, human umbilical cord blood-derived
MSCs (hUC-MSCs) are poorly immunogenic and show
immunosuppressive effects (10,11), thereby facilitating
graft tolerance.
Because the incidence of spontaneous chondrogenic
differentiation of MSCs is very low, many pharmacological
and genetic approaches have been developed to induce
such differentiation (12). SRY-related high-mobility-group
box 9 (Sox9) gene is a cartilage-specific transcription
factor and plays essential roles in chondrocyte differentia-
tion and cartilage formation (13). Sox9 is responsible for
the expression of several cartilage-specific ECM compo-
nents including aggrecan and collagens II, IX, and XI (14),
and compelling evidence indicates that Sox9 is involved in
chondrogenesis of MSCs (15,16). Kawakami et al. (15)
reported that overexpression of Sox9 and its coactivator
(i.e., peroxisome proliferator-activated receptor gamma
coactivator 1-alpha) induces expression of chondrogenic
genes, followed by chondrogenesis in MSCs. The delivery
of Sox9 was found to enhance chondrogenic differentia-
tion but to decrease osteogenic and/or adipogenic
differentiation in human bone marrow-derived MSCs (16).
Despite many studies on the committed differentiation
of bone marrow-derived MSCs, relatively less attention
has been paid to promotion of chondrogenesis in hUC-
MSCs. Given the master role of Sox9 in chondrogenesis,
in the present study we investigated the feasibility of




Human umbilical cords were obtained and processed
within 24 h after delivery of neonates. All procedures
were approved by the Ethics Committee of Xi’an Jiaotong
University (China). Umbilical cord blood samples were
diluted 1:1 in phosphate-buffered saline (PBS) and mixed
with 3% gelatin to deplete red blood cells. The plasma
fraction was collected and centrifuged at 2500 g for 5 min,
and the cellular pellet was resuspended in alpha-minimum
essential medium (a-MEM). The cell suspension was
transferred to centrifuge tubes containing twice the
volume of Ficoll-Paque solution (Sigma, USA) at a density
of 1.077 g/mL, and subjected to centrifugation at 2500 g
for 20 min to isolate the fraction of mononuclear cells that
contained MSCs (17). The isolated cells were washed
twice with D-Hank’s buffer and cultured at a density of
16106 cells/cm2 in a-MEM containing 20% fetal bovine
serum (FBS) and 1% antibiotic/antimycotic (Sigma). The
relatively high plating density facilitates rapid growth and
expansion and assists cell survival. The culture medium
was changed every 2 days, and cells were subcultured
when they reached about 50% confluence.
Cell proliferation assay
To evaluate the effect of cryopreservation on the
proliferation potential of hUC-MSCs, cells at passage 3
were pelleted, resuspended in a-MEM containing 20%
FBS and 10% dimethyl sulfoxide, and cryopreserved in
liquid nitrogen for 3 months. After thawing, the cryopre-
served cells were seeded at a density of 16104 cells/well
onto 24-well plates and cultured in a-MEM supplemented
with 20% FBS. Noncryopreserved cells were also cultured
under the same conditions as described above. The
adherent cells were counted daily for 8 days, and growth
curves were plotted as total cell number vs time.
Immunophenotyping of hUC-MSCs by flow cytometry
Freshly isolated hUC-MSCs were harvested by treat-
ment with 0.1% trypsin-EDTA, and detached cells were
washed with PBS and incubated at 46C for 30 min with
the following mouse anti-human antibodies: anti-CD34,
-CD44, -CD45, -CD105, -CD73, -CD90, -CD19, -CD14,
and major histocompatibility complex class II (MHC II).
These antibodies were conjugated with either fluorescein
isothiocyanate (FITC) or phycoerythrin (PE) (both from
Becton Dickinson, USA). FITC- or PE-conjugated IgG1
was used as isotype control. After they were washed,
labeled cells were assayed by flow cytometry (Becton
Dickinson).
Transfection of Sox9-expressing plasmids
The hUC-MSCs were seeded at 56105 cells per well
on 6-well plates. At 80-90% confluence, the cells were
transfected with an empty vector or Sox9-expressing
plasmid with a green fluorescent protein (GFP) tag at the
N-terminal end using Lipofectamine 2000 reagent,
according to the manufacturer’s instructions (Invitrogen,
USA). After 6 h of transfection, the medium containing
transfection reagents was removed and fresh culture
medium containing 10% FBS was added to the cells.
280 Z.H. Wang et al.
Braz J Med Biol Res 47(4) 2014 www.bjournal.com.br
Transfection efficiency was determined by estimating
the percentage of GFP-positive cells under fluorescence
microscopy 48 h posttransfection.
Chondrogenic differentiation of hUC-MSCs
hUC-MSCs at passage 3 were used to induce
chondrogenic differentiation. The cells were divided into
four groups: untreated control group, differentiation-
induced (DI) group, Sox9 group, and empty vector group.
In the DI group, cells were cultured in chondrogenic
medium (18) containing high-glucose Dulbecco’s modified
Eagle’s medium, 5% FBS, 100 nM dexamethasone,
50 mg/mL ascorbate-2-phosphate, 10 ng/mL recombinant
transforming growth factor-b, 10 ng/mL recombinant
insulin-like growth factor-I, and ITS+ Premix (Sigma). In
the Sox9 and empty vector groups, hUC-MSCs were
transfected with Sox9-expressing plasmid and empty
vector, respectively, in the presence of G418 (600
mg/mL). After incubation for 10 days, the cells were
transferred to G418-free medium and cultured for another
11 days. Chondrogenic differentiation was assessed by
toluidine blue (Sigma) staining.
Reverse transcription-polymerase chain reaction (RT-
PCR)
Total RNA was extracted from treated and untreated
cultures using TRIzol reagent according to the manufac-
turer’s protocol (Invitrogen). First-strand cDNA was
synthesized using the PrimeScript RT-PCR reagent kit
(Takara, China), according to the manufacturer’s instruc-
tions. The specific primers used for RT-PCR are shown in
Table 1. b-actin was amplified as an internal control for
normalization. PCR products were separated on 1.5%
agarose gels and visualized by ethidium bromide staining
(19), and the images were analyzed by the GEL DOC
2000 system (Bio-Rad, USA), where relative expression
level (%) equaled gene band density divided by b-actin
band density.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde for 30 min
and treated with methanol and 0.1% Triton X-100 to
achieve cell membrane and nuclear membrane perme-
ability (20). Nonspecific binding was blocked by incuba-
tion with normal goat serum for 30 min. The hUC-MSCs
were incubated with 1:200 mouse anti-human collagen II
or goat anti-human aggrecan antibody overnight at 46C,
and biotinylated secondary antibody was applied for
30 min at room temperature. After they were thoroughly
washed with PBS containing 1% bovine serum albumin,
the cells were incubated with horseradish peroxidase
(HRP)-labeled streptavidin (ABC kit, Vector Laboratories,
USA), followed by reaction with diaminobenzidine
(Sigma). A negative control was included without addition
of primary antibody. Cells were photographed with an
Olympus IX 70 microscope, and gray density was
analyzed using an image analysis system (Leica,
Germany).
Western blotting analysis
Cells were lysed in lysis buffer [50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1% nonylphenoxypolyethoxyethanol (NP)-
40, and 0.1% sodium dodecyl sulfate (SDS) supplemented
with protease and phosphatase inhibitors]. The protein
extracts were separated on 12% polyacrylamide gels
containing 0.1%SDSand then transferred to a nitrocellulose
membrane. After it was blocked for 4 h in buffer containing
5% fat-free dried milk and 0.5% Tween-20, the membrane
was incubated with anti-collagen II monoclonal antibody
or anti-b-actin polyclonal antibody overnight at 46C. The
membrane was washed three times and incubated for 1 h
with HRP-conjugated goat anti-rabbit IgG (dilution 1:7000)
Table 1. Primers used for RT-PCR.
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or anti-mouse IgG (dilution 1:8000) at room temperature.
The signals were visualized with the enhanced chemilumi-
nescence method and developed on X-ray film. The band
density was measured by the GEL DOC 2000 system
equipped with the Quantity One software (Bio-Rad) and
normalized against the density of b-actin.
Statistical analysis
Data are reported as means±SD from three inde-
pendent experiments and were evaluated by one-way
analysis of variance followed by the Tukey multiple
comparison test. A difference was defined as significant
at P,0.05. All analyses were carried out using the SPSS
10.0 statistical software (SPSS, USA).
Results
Morphology and phenotype characteristics of
umbilical cord blood-derived cells
When grown in monolayer culture, the cells isolated
from umbilical cord blood initially exhibited a spindle-
shaped or polygonal morphology (Figure 1A). After five
passages, the cell culture had a predominantly fibroblast-
like morphology and often formed a squamous eddy-like
structure (Figure 1B). Phenotypic characterization
revealed that the cells were positive for several MSC
markers including CD44, CD105, CD73, and CD90, but
negative for the differentiation markers CD34, CD45,
CD19, CD14, or MHC II (Figure 1C). Compared with
noncryopreserved cells, the cryopreserved counterparts
had a slightly longer latency period and lower proliferation
index (Supplementary Figure S1). However, the differ-
ences were not statistically significant (P.0.05), and they
had a comparable doubling time.
Effects of Sox9 overexpression on morphology and
chondrogenesis of hUC-MSCs
Next, we examined the effects of enforced expression
of Sox9 on the morphology and chondrogenesis of hUC-
MSCs. The transfection efficiency (as determined by the
percentage of GFP-positive cells 48 h after transfection)
was estimated to be about 80% (Supplementary Figure
S2). Cells transfected with either empty vector or Sox9-
expressing plasmid had a fibroblast-like morphology
similar to untreated control cells, without evident detach-
ment (Figure 2A). In contrast, cells cultured in the
chondrogenic medium were polygonal or irregular in
shape and prone to detach from the plate (Figure 2A).
After 2-3 weeks of monolayer culture, Sox9-transfected
hUC-MSCs and those treated with chondrogenic medium
showed a similar accumulation of sulfated proteoglycans
by toluidine blue staining (Figure 2B). However, toluidine
blue staining was weak in untreated and empty vector-
transfected control cells cultured in basic maintenance
medium, suggesting the absence of chondrogenic differ-
entiation (Figure 2B).
Figure 1. Characterization of hUC-MSCs. A, hUC-MSCs at passage 1 displayed a spindle-shaped or polygonal morphology in
monolayer culture. B, hUC-MSCs at passage 5 became a predominant fibroblast-like morphology and formed a squamous eddy-like
structure. Bar = 50 mm. C, Flow cytometric analysis of surface antigen markers. hUC-MSCs expressed CD44, CD105, CD73, and
CD90, but not CD34, CD45, CD19, CD14, or MHC II. PE- and FITC-conjugated mouse monoclonal IgG1 were used as isotype controls.
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Induction of aggrecan and type II collagen expression
by Sox9 overexpression
RT-PCR analysis revealed elevated mRNA expression
of both aggrecan and type II collagen in Sox9-transfected
cells vs empty vector-transfected counterparts (Figure 3).
Moreover, such elevation was found to be time-dependent
for up to 10 days of culture. However, no detectable level of
the type I collagen transcript was observed in the Sox9
group. After 2 weeks of culture, cells grown in chondro-
genic medium had a significant increase in the mRNA
expression of aggrecan and type I and type II collagens
compared to untreated control cells.
Immunocytochemistry further demonstrated that
genetic delivery of Sox9 markedly enhanced the expres-
sion of aggrecan and type II collagen in hUC-MSCs,
compared with empty vector-transfected counterparts
(Figure 4). Such enhancement was similar to that seen
in the group treated with chondrogenic medium (Figure 4).
Discussion
Because of easy availability, multilineage differentia-
tion potential, few ethical concerns, and low immunogeni-
city, MSCs are promising candidates for tissue
engineering (21). Although bone marrow is the main
source, MSCs have already been isolated from various
other tissues, such as adipose tissue (22) and umbilical
cord (23). Choudhery et al. (24) reported that confluent
cultures of MSCs either from adipose tissue or cord tissue
show a fibroblastic morphology. They further demon-
strated that the isolated MSCs are positive for CD44,
CD73, CD90, and CD105 and negative for the hemato-
poietic markers CD3, CD14, CD19, CD34, and CD45.
Functional studies revealed that MSCs derived from
adipose and cord tissue can efficiently differentiate into
adipose, bone, cartilage, and neuronal structures (24). In
accordance with these findings, we observed that
umbilical cord blood-derived cells in monolayer culture
had a fibroblast-like morphology. Moreover, these cells
displayed phenotypic characteristics typical of MSCs, as
evidenced by expression of CD44, CD105, CD73, and
CD90 and lack of expression of CD34, CD45, CD19,
CD14, and MHC II. Despite similar morphology and
molecular phenotype, MSCs from different sources vary
in proliferation potential. It has been suggested that
umbilical cord blood-derived MSCs have the highest
proliferation capacity, followed by adipose tissue-derived
MSCs and bone marrow-derived MSCs (24-26).
Therefore, umbilical cord blood is an attractive alter-
native to bone marrow for large-scale production of
MSCs.
Genetic modification is a powerful tool to induce
committed differentiation of MSCs. We found that
transfection with an empty vector or Sox9-expressing
plasmid has little influence on the cell morphology of hUC-
MSCs. In contrast, hUC-MSCs cultured in the chondro-
genic medium underwent a morphological change to
polygonal or irregular cells and were prone to detach from
Figure 2. Effects of Sox9 overexpression on morphological changes and proteoglycan disposition in hUC-MSCs. A, Untreated hUC-
MSCs and those transfected with empty vector or Sox9-expressing plasmid had a similar fibroblast-like morphology. In contrast, hUC-
MSC cells cultured in the chondrogenic medium (differentiation-induced group: DI) for 48 h were polygonal or irregular in shape and
prone to detach from the plate. Bar = 50 mm. B, Assessment of proteoglycan disposition by toluidine blue staining. The degree of
toluidine blue staining was low in untreated and empty vector-transfected control hUC-MSC cells with basic maintenance medium. After
2-3 weeks of monolayer culture, Sox9-transfected hUC-MSCs and those treated with chondrogenic medium (DI) showed strong
toluidine blue staining. Bar = 100 mm.
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the plate. These findings reflect that gene transfection
causes lower toxicity to hUC-MSCs than the addition of
chondrogenic growth factors. Numerous molecular factors
have been identified as responsible for promoting chondro-
genic differentiation of MSCs (27,28). It has been docu-
mented that exogenous administration of transforming
growth factor-beta 1 (TGF-b1) efficiently stimulates chon-
drogenesis of human MSCs in pellet cultures (29). Bone
morphogenetic protein (BMP)-4 and BMP-2 are also
effective in provoking chondrogenesis of primary human
MSCs in pellet culture (28). However, chondrogenesis
triggered by BMP-2 and BMP-4 gene transfer showed
considerable evidence of hypertrophic differentiation. Sox9
is a well-established inducer of chondrogenesis, controlling
the expression of numerous cartilage ECM components
(15). Furumatsu et al. (30) reported that Smad3 over-
expression strongly induces the primary chondrogenesis of
human MSCs through activation of Sox9-dependent
transcription. Silencing of Sox9 using RNA interference
technology abrogates TGF-b1-induced chondrogenic dif-
ferentiation of human bonemarrow-derivedMSCs (31). Our
present data confirm the master role of Sox9 in chondro-
genesis, as evidenced by the finding that Sox9 over-
expression significantly raised proteoglycan deposition and
enhanced the expression of aggrecan and type II collagen
in hUC-MSCs. Additionally, we found that Sox9 over-
expression significantly inhibited the expression of type I
collagen. It has been shown that hypertrophic chondrocytes
extensively synthesize type I collagen and type X collagen
(32). These findings suggest that short-term genetic
delivery of Sox9 can efficiently direct chondrogenic
differentiation of hUC-MSCs, without inducing hypertrophy.
However, it has been found that continued expression of
Sox9 in differentiated chondrocytes results in subsequent
Figure 3. RT-PCR analysis of the mRNA expression of Sox9,
collagen I, collagen II, and aggrecan in untreated hUC-MSCs
cells and those transfected with empty vector or Sox9-expressing
plasmid or induced with the chondrogenic medium (differentia-
tion-induced group: DI). Representative gel photographs of RT-
PCR products from three independent experiments are shown.
d: days.
Figure 4. Sox9 overexpression induces chondrogenic differentiation in hUC-MSC cells. For induction of chondrogenic differentiation,
cells were treated as described in Material and Methods. After the treatments, cells were subjected to immunocytochemistry for
aggrecan and collagen II. Similar to the treatment with chondrogenic medium, genetic delivery of Sox9 markedly enhanced the
expression of aggrecan and type II collagen in hUC-MSCs. DI: differentiation-induced group. Bar = 50 mm.
284 Z.H. Wang et al.
Braz J Med Biol Res 47(4) 2014 www.bjournal.com.br
hypertrophy (33). Therefore, an inducible gene delivery
system may be required for efficient control of Sox9
expression during the chondrogenesis of MSCs.
Some limitations of this study should be noted. First,
there is no information on the impact of Sox9 over-
expression on the proliferation and multilineage differ-
entiation potential of MSCs. Second, it remains unclear
what may be the long-term effects of sustained expres-
sion of Sox9 on the molecular and functional charac-
teristics of MSCs. Finally, there is no mechanistic
investigation of Sox9-mediated chondrogenesis of
hUC-MSCs.
In conclusion, our results demonstrate that human
umbilical cord blood is an important source of MSCs, and
enforced expression of Sox9 accelerates the chondrogenic
differentiation of hUC-MSCs. Therefore, Sox9-based
genetic modification of hUC-MSCs may be an attractive
cell source for cartilage tissue engineering.
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